Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Classical & Lectin Pathway Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for C2-targeted drug discovery. Sequence-verified antigens and functional validators for hemolysis and C3 convertase assays.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Human C2 Recombinant Protein (Full-length, HEK293 expressed, >95% purity, Endotoxin <1 EU/µg, Sequence Verified). Also available as C2 ECD-Fc/Mutant. | View C2 Products |
| C2a Protease Domain | Recombinant C2a domain for proteolytic activity studies. | View C2 Products |
| Species Ortholog | Cynomolgus/Mouse C2 Protein for preclinical cross-reactivity and toxicology bridging. Theoretical MW verified. | View C2 Products |
| Gene Delivery | C2 ORF Lentivirus Particles; Promise-ORF for stable hepatocyte cell lines and secreted expression. | View C2 Products |
| Validator | C2-specific siRNA Set for knockdown verification and pathway specificity confirmation. | View C2 Products |
| Benchmark Ab | Anti-C2 Neutralizing Antibody (Reference Clone); recombinant positive control for functional hemolysis assays and SPR/BLI. | View C2 Products |
| Related Target | C1S (Complement C1s) – Upstream serine protease that cleaves C2; synergistic co-target. | View C1S Products |
| Related Target | C4A (Complement C4) – Binding partner of C2a in C3 convertase (C4b2a); essential for epitope competition assays. | View C4A Products |
| Related Target | CFB (Complement Factor B) – Alternative pathway counterpart; selectivity counter-screening. | View CFB Products |
Critical Assay Challenges
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Classical Pathway Functional Restoration (CH50) | High-purity C2 protein restores hemolytic activity in C2-deficient serum; endotoxin controlled to <1 EU/µg to prevent false activation. |
| Cross-Species Translation (Cyno/Mouse) | Human, Cynomolgus, and Mouse C2 orthologs available with >95% purity and sequence-verified identity for toxicology bridging. |
| Proteolytic Cleavage Detection | Native C2 full-length (zymogen) and C2a/C2b domain proteins available for C1s protease interaction and convertase assembly studies. |
| Zymogen vs. Active Protease Distinction | Purified full-length C2 (zymogen) and activated C2a domain for mechanism-of-action studies. |
| Pathway Selectivity (Classical vs. Alternative) | C2 siRNA and C1S antigen for discrete pathway node analysis; CFB protein for counter-screening. |
| False Positives / Background Activation | Endotoxin controlled to <1 EU/µg; endotoxin-free formulation available. |
Live C2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (C2 complement inhibitor)
- ➤ Latest Classical Pathway Research
- ➤ Recent Patent Filings (RNAi & small molecule)
Global Clinical Landscape & Future Outlook
The race for C2-targeted therapeutics represents a strategic shift toward selective classical/lectin pathway inhibition while preserving alternative pathway defense mechanisms. Major players are moving beyond terminal pathway (C5) inhibitors to upstream specific modulators. Arrowhead's ARO-C2 (Phase 2) and Ionis's IONIS-C2-LRx (Phase 1/2) lead with liver-targeted RNAi approaches for durable C2 depletion in cold agglutinin disease (CAD) and antibody-mediated rejection (AMR). Meanwhile, first-generation C1s inhibitors (Sutimlimab) have established proof-of-concept, and the next wave of C2-directed R&D targets improved safety profiles in chronic autoimmune indications, renal diseases, and neurodegenerative conditions. The modality landscape is diversifying: monoclonal antibodies, small molecule inhibitors (targeting C2 protease activity), and RNAi/ASO are all in play. Future trends include subcutaneous/long-acting formulations and expansion into larger indications (e.g., lupus nephritis, IgA nephropathy).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| RNAi (GalNAc-siRNA) | Arrowhead (ARO-C2), Alnylam | Cold Agglutinin Disease, AMR | Plasma C2 level quantification (Sandwich ELISA), CH50 functional assay; need high-purity C2 standards. |
| Antisense (ASO-LICA) | Ionis (IONIS-C2-LRx) | Autoimmune Hemolysis | qPCR-grade mRNA detection reagents; species-specific protein standards. |
| Monoclonal Antibodies | Sanofi, Alexion, Apellis, [Emerging Preclinical] | CAD, Autoimmune disease | High-concentration binding assays (C2 plasma ~25 mg/L); sub-nM affinity required; need native-like recombinant C2. |
| Small Molecule Inhibitors | Novartis, BioCryst | Renal Diseases (IgAN, MN), Oral complement inhibition | Protease activity/selectivity assays; need fully functional C2 and C2a for C1s cleavage assays. |
Molecular Insights: Domains & Key Mutations
Complement C2 is a serine protease containing three Sushi (CCP) domains (UniProt P06681), which mediate interactions with C4b and complement regulators. The protein is activated by C1s-mediated cleavage, releasing the C2a catalytic domain. Key mutations located in the C2D (C2 deficiency) region include:
- rs760744400: Associated with C2 deficiency.
- rs28934590: Associated with C2 deficiency.
- rs (VAR_019158): May be associated with reduced risk for age-related macular degeneration. These mutations impact classical pathway function and are critical for genetic screening and companion diagnostic development.
Deduplication Summary
Three candidates were merged. The solution ecosystem table was consolidated by combining all unique components (e.g., Species Ortholog, C2a Domain, CFB) from relay_kimi and relay_gemini. The critical assay challenges table merged distinct rows (Zymogen vs. Active from native_kimi). Global landscape paragraphs were fused to cover both RNAi specifics (relay_kimi) and broader industry shift (relay_gemini). The modality snapshot retained relay_kimi's detailed structure while incorporating relay_gemini's additional players (Sanofi, Novartis, BioCryst) and indications. A new section on Domains & Mutations was added based on fact_payload to increase information density.